Takeda Pharmaceutical (NYSE:TAK) Hits New 1-Year High – Should You Buy?

Shares of Takeda Pharmaceutical Co. (NYSE:TAK) reached a new 52-week high on Monday . The company traded as high as $15.74 and last traded at $15.7350, with a volume of 158136 shares trading hands. The stock had previously closed at $15.65.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “hold (c-)” rating on shares of Takeda Pharmaceutical in a research note on Monday, December 22nd. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold”.

Takeda Pharmaceutical Price Performance

The company has a debt-to-equity ratio of 0.61, a current ratio of 1.37 and a quick ratio of 0.76. The firm has a market capitalization of $50.13 billion, a P/E ratio of 196.69 and a beta of 0.03. The company’s 50 day moving average price is $14.28 and its 200 day moving average price is $14.61.

Takeda Pharmaceutical (NYSE:TAK) last posted its quarterly earnings data on Thursday, October 30th. The company reported $0.44 earnings per share for the quarter, hitting the consensus estimate of $0.44. The firm had revenue of $7.30 billion during the quarter, compared to analysts’ expectations of $8.01 billion. Takeda Pharmaceutical had a net margin of 0.86% and a return on equity of 10.32%. Takeda Pharmaceutical has set its FY 2025 guidance at 3.250-3.250 EPS. As a group, sell-side analysts anticipate that Takeda Pharmaceutical Co. will post 1.64 EPS for the current fiscal year.

Institutional Trading of Takeda Pharmaceutical

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Invesco Ltd. bought a new position in shares of Takeda Pharmaceutical in the 1st quarter valued at about $743,000. Ieq Capital LLC boosted its stake in Takeda Pharmaceutical by 4.6% in the first quarter. Ieq Capital LLC now owns 22,222 shares of the company’s stock valued at $330,000 after acquiring an additional 981 shares during the last quarter. Vident Advisory LLC grew its holdings in Takeda Pharmaceutical by 52.4% during the 1st quarter. Vident Advisory LLC now owns 20,732 shares of the company’s stock worth $308,000 after acquiring an additional 7,126 shares during the period. Baird Financial Group Inc. acquired a new stake in Takeda Pharmaceutical during the 1st quarter worth $276,000. Finally, Nomura Holdings Inc. bought a new stake in shares of Takeda Pharmaceutical during the 1st quarter valued at $338,000. 9.17% of the stock is owned by institutional investors.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.